Conclusion There are continuing advancements in multimodal analgesic techniques;
however, postoperative pain in general continues to be undermanaged. Furthermore, a …

Introduction: Central sensitization (CS) is present in a variety of chronic pain disorders,
including whiplash, temporomandibular disorders, low back pain, osteoarthritis …

Tramadol and tapentadol are centrally acting, synthetic opioid analgesics used in the
treatment of moderate to severe pain. Main metabolic patterns for these drugs in humans are …

Pain is a common symptom in many types of cancer. Interdisciplinary team management,
including pain assessment, explanation to the patient/family, treating the reversible, non …

Objective To evaluate the effectiveness of tapentadol prolonged release (PR) vs.
oxycodone/naloxone PR in non–opioid‐pretreated patients with severe chronic low back …

Introduction The distinct properties of the centrally-acting analgesic tapentadol derive from
the combined contributions of an opioid component and a nonopioid component. However …

Background A large proportion of people with advanced cancer will experience moderate to
severe pain. Tapentadol is a novel, centrally acting analgesic medicine acting at the μ …

Opioid analgesics are highly effective painkillers for the treatment of moderate or severe
pain, but they are associated with a number of undesirable adverse effects, including the …

Tapentadol prolonged release (PR) for the treatment of moderate to severe chronic pain
combines 2 modes of action. These are μ‐opioid receptor agonism and noradrenaline …

Managing chronic pain remains a major unmet clinical challenge. Patients can be treated
with a range of interventions, but pharmacotherapy is the most common. These include …